Stock Ratings / Health Care / EBS / insiders

RLMD (30) SPRY (20) CYPH (45) GALT (39) ⌘ Pro Terminal →

Emergent BioSolutions Inc. (EBS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.81 -5.68% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.73

Emergent BioSolutions Inc. (EBS) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $370.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EBS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Emergent BioSolutions Inc. (NYSE: EBS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $6.81 (-5.68% 1D, market cap $370.2M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, EBS ranks #270 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EBS compare to RLMD and SPRY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EBS carries a Roarable D+ (52/100 RQD), trailing P/E of 7.0x, gross margin of 56.1%, and ROIC of 8.9%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and SPRY (ARS Pharmaceuticals Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EBS?

▼

Per EBS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001367644), Emergent BioSolutions Inc. generated $742.9M in revenue (-28.8% YoY), $52.6M in net income, and $156.8M in free cash flow against $1.32B in total assets and $572.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.73 (-1.21%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 21.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-2.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EBS)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY EBS SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+13/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 21.1% FCF Margin ($156.8M FCF) & 56.1% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 65% Net Buy • Cannibal Buyback (-1.52% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (59.1) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$6.98-8.9% Next Q

Q2 (-2Q)

Grade C$6.36-0.3% Next Q

Q3 (-1Q)

Grade C$6.34+7.4% Next Q

Current

Grade D+$6.81-1.1% Hist 90D α

Trajectory: C (60) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EBS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EBS currently carries a cautious 52/100 (D+) rating due to Macro Regime Fit (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.51) and Max Pain ($7.15) forces dealer call-delta covering toward $14.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EBS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EBS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

EBS Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (EBS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on EBS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EBS)

✓Walkthrough of EBS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EBS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.26%⚡ TESTING RESISTANCE

2026-11-02O $7.09H $7.22L $6.81C $6.81VOL 682.4K

RES: $7.25SUP: $6.20SMA50: $6.51SMA200: $7.99

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EBS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EBS Butterfly Map → + Track EBS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.0%/yr Implied 5Y Growth

vs. -28.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EBS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EBS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EBS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EBS)

Health Care Rank #270 of 1016 ⚔️ RLMD vs EBS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EBS vs. RLMD, SPRY, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Emergent BioSolutions Inc. (EBS) ranks #270 by composite RQD confidence (52/100, grade D+) and #492 by equity capitalization ($370.2M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EBS ACTIVE Emergent BioSolutions Inc.	D+	52/100	7.0x	56.1%	8.9%	-5.68%	$370.2M	Benchmark Subject
RLMD Relmada Therapeutics Inc.	E	30/100	—	—	-35.0%	+4.07%	$366.9M	/rlmd-vs-ebs →
SPRY ARS Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-7.65%	$364.0M	/spry-vs-ebs →
CYPH Cypherpunk Technologies Inc.	D	45/100	71.3x	—	-23.3%	-9.97%	$356.7M	/cyph-vs-ebs →
GALT Galectin Therapeutics Inc.	D-	39/100	—	—	-35.0%	-5.68%	$355.8M	/galt-vs-ebs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001367644

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Emergent BioSolutions Inc. (EBS) reported GAAP revenue of $742.9M (-28.8% vs. FY2024 revenue of $1.04B , and -29.2% cumulative change since FY2023) , GAAP net income of $52.6M, operating cash flow of $170.6M, and free cash flow of $156.8M (+338.0% YoY). On the balance sheet, EBS closed FY2025 with $1.32B in total assets against $572.1M in total debt (Altman Z-Score: 1.41, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$742.9M	$52.6M	$170.6M	$156.8M	$1.32B	$572.1M
FY2024 (FY)	2024-12-31	$1.04B	-$190.6M	$58.7M	$35.8M	$1.39B	$663.7M
FY2023 (FY)	2023-12-31	$1.05B	-$760.5M	-$206.3M	-$206.3M	—	—

3. EBS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EBS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EBS compare to RLMD and SPRY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EBS?

Where is EBS trading relative to its 50-day, 200-day, and 52-week technical levels?

EBS last traded at $6.81 (-5.68% on volume of 754,456 shares), positioning the stock +4.61% above its 50-day simple moving average ($6.51) and -14.77% below its 200-day simple moving average ($7.99). Across its 52-week range of $4.36 to $14.06, EBS sits at the 25.3% percentile with a 14-day RSI of 59.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.3% ($6.04 to $7.58).

EBS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are EBS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies EBS leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: EBS RQD Cockpit EBS 12M Forecast EBS Earnings & Move EBS Dividends & DRIP EBS Insiders & 13F EBS Whale Options EBS Profit Sankey EBS News & Why